VAXART ($VXRT) posted quarterly earnings results on Thursday, March 20th. The company reported earnings of -$0.05 per share, beating estimates of -$0.10 by $0.05. The ...

Full Year 2025 Revenue: $237.3 million, compared to $28.7 million for the full year 2024. Cash, Cash Equivalents, and Investments: $63.8 million at the end of the fourth quarter. Cash Runway: Expected ...

Vaxart (VXRT) has shared an announcement. Vaxart, Inc. stockholders have given the green light for significant expansions to the company’s equity plans and an increase in authorized shares. This move, ...

Vaxart, Inc. (NASDAQ:VXRT) Q4 2025 Earnings Call Transcript March 12, 2026 Vaxart, Inc. beats earnings expectations. Reported ...

Oppenheimer initiated coverage on Vaxart Inc. (NASDAQ:VXRT), an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines. The analyst’s ...

Vaxart (NASDAQ:VXRT) shares rose in post-market trading on Wednesday after the company announced the publication of complete data from a Phase 2 trial for its oral pill norovirus vaccine candidate in ...

Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine ...

Vaxart Inc (NASDAQ:VXRT) shares are trading higher in Monday’s after-hours session after the company provided business and cash runway updates. What Happened: Vaxart, a clinical-stage biotechnology ...

Greetings. Welcome to the Vaxart Business Update and First Quarter 2025 Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. Individual investors ...